287 related articles for article (PubMed ID: 10472344)
21. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
22. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
23. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
24. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
25. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
26. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
28. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
30. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
31. Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Myerson R; Zobeiri I; Birnbaum E; Dietz D; Fleshman J; Kodner I; Picus J; Ratkin G
Semin Oncol; 2002 Dec; 29(6 Suppl 19):29-33. PubMed ID: 12577240
[TBL] [Abstract][Full Text] [Related]
32. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
McCumber LM
Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
[TBL] [Abstract][Full Text] [Related]
33. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
34. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.
Andreassen CN; Grau C; Lindegaard JC
Semin Radiat Oncol; 2003 Jan; 13(1):62-72. PubMed ID: 12520465
[TBL] [Abstract][Full Text] [Related]
35. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
Ng AK; Hickey G; Li S; Neuberg D; Mauch PM
Semin Oncol; 2004 Dec; 31(6 Suppl 18):20-4. PubMed ID: 15726518
[TBL] [Abstract][Full Text] [Related]
37. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
38. Amifostine and radiation therapy: past, present, and future.
Tannehill SP; Mehta MP
Semin Oncol; 1996 Aug; 23(4 Suppl 8):69-77. PubMed ID: 8783671
[TBL] [Abstract][Full Text] [Related]
39. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
40. Amifostine and curative intent chemoradiation for compromised cancer patients.
Nguyen NP; Levinson B; Dutta S; Karlsson U; Kelly KC; Dowell J; Ludin A; Sallah S
Anticancer Res; 2003; 23(2C):1649-56. PubMed ID: 12820436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]